Please assess the completion status of the following clinical trial:

Trial Title: A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* outpatient~* signed and dated written informed consent~* 40 years of age or older~* male and female subjects~* COPD diagnosis~* at least 10 pack-year smoking history~* post-albuterol/salbutamol FEV1/FVC ratio of \<0.70 and post-albuterol/salbutamol FEV1 greater than or equal to 35% and less than or equal to 80% of predicted normal~Exclusion Criteria:~* Pregant or lactating women or women planning to become pregnant during the study~* current diagnosis of asthma~* other respiratory disorders other than COPD~* other diseases/abnormalities that are uncontrolled including cancer not in remission for at least 5 years~* chest x-ray or CT scan with clinically significant abnormalities not believed to be due to COPD~* hypersensitivity to anticholinergics, beta-agonists, lactose/milk protein or magnesium stearate or medical conditions associated with inhaled anticholinergics~* hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1~* lung volume reduction surgery within 12 months prior to Visit 1~* abnormal and clinically significant ECG at Visit 1~* abnormal and clinically significant Holter monitor finding at Visit 1~* significantly abnormal finding from laboratory tests at Visit 1~* unable to withhold albuterol/salbutamol and/or ipratropium bromide at least 4 hours prior to spirometry at each visit~* use of depot corticosteroids within 12 weeks of Visit 1~* use of oral or parenteral corticosteroids within 6 weeks of Visit 1~* use of anitbiotics for lower respiratory tract infection within 6 weeks of Visit 1~* use of cytochrome P450 3A4 inhibitors within 6 weeks of Visit 1~* us of long-acting beta-agonist (LABA)/inhaled corticosteroid (ICS) products if LABA/ICS therapy is discontinued completely within 30 days of Visit 1~* use of ICS at a dose of \>10000mcg/day of fluticasone propionate or equivalent within 30 days of Visit 1~* initiation or discontinuation of ICS within 30 days of Visit 1~* use of tiotropium within 14 days of Visit 1~* use of roflumilast within 14 days of Visit 1~* use of theophyllines within 48 hours of Visit 1~* use of oral leukotriene inhibitors within 48 hours prior to Visit 1~* use of long-acting oral beta-agonists within 48 hours of Visit 1~* use of short-acting oral beta-agonists within 12 hours of Visit 1~* use of inhaled long-acting beta-agonists within 48 hours prior to Visit 1~* use of LABA/ICS combination products only if discontinuing LABA therapy and switching to ICS monotherapy within 48 hours of Visit 1 for the LABA component~* use of sodium cromoglycate or nedocromil sodium within 24 hours of Visit 1~* use of inhaled short acting beta-agonists within 4 hours of Visit 1~* use of inhaled short-acting anticholinergics within 4 hours of Visit 1~* use of inhaled short-acting anticholinergic/short-acting beta2-agonist combination products within 4 hours of Visit 1~* use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer) of Visit 1~* long-term oxygen therapy prescribed for \>12 hours per day~* regular use of short-acting bronchodilators~* use of CPAP or NIPPV~* participation in the maintenance phase of a pulmonary rehabilitation program~* known or suspected history of alcohol or drug abluse with 2 years prior to Visit 1~* anyone affiliated with the investigator site (e.g., investigator, study coordinator, etc.)~* previous use of GSK573719, GW642444 , GSK573719/GW642444 combination, GSK233705/GW642444 combination, or Fluticasone Furoate/GW642444 combination

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- GSK573719/GW642444 (Type: EXPERIMENTAL): 125/25 mcg once-daily
- GSK573719 (Type: EXPERIMENTAL): 125 mcg once-daily
- Placebo (Type: PLACEBO_COMPARATOR): inactive

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete